Follow
Kaushik Thakkar
Kaushik Thakkar
Senior Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson
Verified email at its.jnj.com
Title
Cited by
Cited by
Year
Biological synthesis of metallic nanoparticles
KN Thakkar, SS Mhatre, RY Parikh
Nanomedicine: nanotechnology, biology and medicine 6 (2), 257-262, 2010
27662010
The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor
Y Xiao, KN Thakkar, H Zhao, J Broughton, Y Li, JA Seoane, AN Diep, ...
Proceedings of the National Academy of Sciences 117 (35), 21441-21449, 2020
742020
TRIM24 links glucose metabolism with transformation of human mammary epithelial cells
TN Pathiraja, KN Thakkar, S Jiang, S Stratton, Z Liu, M Gagea, X Shi, ...
Oncogene 34 (22), 2836-2845, 2015
552015
The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling
EJ Moon, SS Mello, CG Li, JT Chi, K Thakkar, JG Kirkland, EL Lagory, ...
Nature communications 12 (1), 4308, 2021
532021
Regulation of gene expression in human cancers by TRIM24
S Appikonda, KN Thakkar, MC Barton
Drug Discovery Today: Technologies 19, 57-63, 2016
482016
Generation of stable expression mammalian cell lines using lentivirus
N Tandon, KN Thakkar, EL LaGory, Y Liu, AJ Giaccia
Bio-protocol 8 (21), e3073-e3073, 2018
432018
Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer
YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, S Nandagopal, ...
Clinical cancer research 27 (15), 4435-4448, 2021
422021
Biological synthesis of metallic nanoparticles
N Thakkar Kaushik, S Mhatre Snehit, Y Parikh Rasesh
Nanomedicine: Nanotechnology and Biology and Medicine 6, 257-262, 2010
292010
Cross-talk between chromatin acetylation and SUMOylation of tripartite motif–containing protein 24 (TRIM24) impacts cell adhesion
S Appikonda, KN Thakkar, PK Shah, SYR Dent, JN Andersen, MC Barton
Journal of Biological Chemistry 293 (19), 7476-7485, 2018
282018
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination–deficient cancer models
M Mehibel, Y Xu, CG Li, EJ Moon, KN Thakkar, AN Diep, RK Kim, ...
The Journal of clinical investigation 131 (11), 2021
192021
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma
YR Miao, K Thakkar, C Cenik, D Jiang, K Mizuno, C Jia, CG Li, H Zhao, ...
Journal of Experimental Medicine 219 (9), e20220214, 2022
72022
Tissue-specific metabolism and TRIM24
KN Thakkar, SA Stratton, MC Barton
Aging (Albany NY) 7 (10), 736, 2015
32015
Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer
AJG Yu Miao, Kaushik N. Thakkar, Jin Qian, Mihalis S. Kariolis, Huang Wei ...
bioRxiV, 2020
22020
Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors.
M Mehibel, J Xu, A Diep, K Thakkar, CG Li, Y Xiao, E Rankin, A Giaccia
Journal of Clinical Oncology 37 (15_suppl), e14715-e14715, 2019
22019
sPD-1 VARIANT–FC FUSION PROTEINS
AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang
US Patent App. 17/962,983, 2023
2023
SPD-1 variant# FC fusion proteins
AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang
US Patent 11,498,955, 2022
2022
Abstract IA-003: Oxygen dependent resistance to PARP inhibitors
M Mehibel, J Xu, G Li, J Moon, K Thakkar, A Diep, R Kim, J Bloomstein, ...
Clinical Cancer Research 27 (8_Supplement), IA-003-IA-003, 2021
2021
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade
YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, N Saravanan, ...
Oncol 152 (2), 243-50, 2019
2019
Reading histone modifications, an oncoprotein is modified in return
News-Article
https://bit.ly/2KKaJdM https://bit.ly/2GGEOZb https://bit.ly/2KOVoc3 https …, 2018
2018
TRIM24 orchestrates metabolic reprogramming and EMT in Breast Cancer
K Thakkar
2016
The system can't perform the operation now. Try again later.
Articles 1–20